Highlights and Quick Summary
- Other financial activities for the quarter ending December 31, 2021 was $822 Thousand (a -22.23% decrease compared to previous quarter)
- Year-over-year quarterly Other financial activities decreased by -6.16%
- Annual Other financial activities for 2021 was $3.73 Million (a -7.92% decrease from previous year)
- Annual Other financial activities for 2020 was $4.05 Million (a 17.37% increase from previous year)
- Annual Other financial activities for 2019 was $3.45 Million (a 23.62% increase from previous year)
- Twelve month Other financial activities ending December 31, 2021 was $3.73 Million (a -2.61% decrease compared to previous quarter)
- Twelve month trailing Other financial activities increased by 109.48% year-over-year
Trailing Other financial activities for the last four month:
| 31 Dec '21 | 30 Sep '21 | 30 Jun '21 | 31 Mar '21 |
|---|---|---|---|
| $3.73 Million | $3.83 Million | $2.77 Million | $1.78 Million |
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Other financial activities of Allena Pharmaceuticals, Inc.
Most recent Other financial activitiesof ALNA including historical data for past 10 years.Interactive Chart of Other financial activities of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Other financial activities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $0.82 | $1.06 | $0.98 | $0.88 | $3.73 |
| 2020 | $0.92 | $-0.01 | $-0.01 | $-0.01 | $4.05 |
| 2019 | $12.03 | $-0.01 | $-0.01 | $-0.01 | $3.45 |
| 2018 | $-0.01 | $-0.05 | $0.18 | $-0.19 | $2.79 |
| 2017 | – | – | – | $-0.57 | $1.16 |
| 2016 | $0.01 | $-0.37 | – | – | $-0.37 |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.